Key Inclusion Criteria:

          1. Subject is ≥ 18 years and ≤ 75 years of age and has voluntarily agreed to participate
             by giving written informed consent in accordance with ICH GCP Guidelines and
             applicable local regulations.

          2. Histologically confirmed HCC, not amenable to transplant, resection. Subjects may
             undergo loco-regional therapy after enrollment but not at time of lymphodepletion. Or
             Histologically confirmed diagnosis of another AFP expressing tumor (e.g.
             cholangiocarcinoma).

          3. Measurable disease according to RECIST 1.1 criteria prior to lymphodepletion.

          4. Progressive disease following or intolerant of or refuses standard of care systemic
             therapy prior to lymphodepletion.

          5. Positive for any A*02:01 P group allele.

          6. a) Group 1, 2, 3, (HCC) Subjects will be eligible for enrollment if they meet either
             one of these AFP expression criteria:

               -  AFP expression of ≥1+ in ≥20% of tumor cells by immunohistochemistry and their
                  non-cancerous liver tissue has ≤5% cells stained for AFP at any intensity by
                  immunohistochemistry.

               -  Serum AFP levels of ≥100ng/mL and their non-cancerous liver tissue has ≤5% cells
                  stained for AFP at any intensity by immunohistochemistry.

        6. b) Group 4 (other AFP expressing tumor types) Subjects will be eligible for enrollment
        if they meet either one of these AFP expression criteria:

        o Serum AFP levels of ≥100ng/mL and their non-cancerous liver tissue (if applicable) has
        ≤5% cells stained for AFP at any intensity by immunohistochemistry.

        7. Life expectancy of > 4 months 8. Child-Pugh score ≤ 6 9. Eastern Cooperative Oncology
        Group (ECOG) 0-1 10. Subject must have adequate organ function as defined in the protocol.

        Key Exclusion Criteria:

          1. Positive for any of the HLA-A*02 allele other than HLA-A*02:01 P Group, HLA-A*02:03 P
             group or null alleles or positive for the following alleles: HLA-C*04:04 or
             HLA-B*51:03.

          2. Prior liver transplant

          3. Received the following prior to leukapheresis:

               1. Cytotoxic chemotherapy, immune therapy and biological therapy within 3 weeks

               2. Corticosteroids or any other immunosuppressive therapy within 2 weeks. NOTE: Use
                  of inhaled or topical steroids is not exclusionary

               3. Sorafenib/Regorafenib/Lenvatinib within 1 week

               4. Cabozantinib within 2 weeks

               5. Duration of treatment free intervals for any other anti-cancer therapies must be
                  discussed with Adaptimmune Study Physician.

          4. Received the following prior to lymphodepleting chemotherapy :

               1. Cytotoxic chemotherapy or loco-regional therapy within 3 weeks, liver directed
                  radiation therapy within three months.

               2. Corticosteroids or any other immunosuppressive therapy within 2 weeks. NOTE: Use
                  of inhaled or topical steroids is not exclusionary

               3. Bone/soft tissue directed palliative radiotherapy within 4 weeks.

               4. Investigational treatment or clinical trial within 4 weeks.

               5. Sorafenib/Regorafenib/Lenvatinib within 1 week.

               6. Cabozantinib within 2 weeks

               7. Prior cancer-directed immunotherapy within 4 weeks, including monoclonal
                  antibodies against PD-1 receptor or ligand.

               8. Use of an experimental vaccine within 2 months in the absence of tumor response.
                  The subject should be excluded if their disease is responding to an experimental
                  vaccine given within 6 months

               9. Any previous gene therapy using an integrated vector

              10. Duration of treatment free intervals for any other anti-cancer therapies must be
                  discussed with Adaptimmune Study Physician.

          5. Toxicity persisting from previous anti-cancer therapy of ≥ Grade 2 (except for
             non-clinically significant toxicities, e.g., alopecia, vitiligo). Subjects with Grade
             2 toxicities that are deemed stable or irreversible (e.g. peripheral neuropathy) can
             be enrolled on a case-by-case basis with prior consultation and agreement with the
             Sponsor Study Physician.

          6. Major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully
             recovered from any surgical related toxicities.

          7. Bleeding ≥ Grade 2 in the past 3 months prior to lymphodepletion

          8. Therapeutic anticoagulation from lymphodepletion until platelet count recovery
             (prophylactic heparin allowed)

          9. Clinically or radiographically detectable ascites (beyond trace/rim of ascites) or
             ascites requiring medication

         10. Clinically detectable hepatic encephalopathy or hepatic encephalopathy requiring
             medication

         11. Active viral hepatitis Subjects positive for hepatitis B surface antigen not on
             antiviral treatment/prophylaxis or subjects with detectable hepatitis B DNA

               1. Subjects with resolved (surface antigen negative, core antibody positive) or
                  chronic stable (surface antigen positive) hepatitis B on antiviral
                  treatment/prophylaxis with DNA levels of ≤100 IU/mL are allowed with HBV DNA
                  monitoring after treatment

               2. Subjects with hepatitis C allowed provided they meet all other eligibility
                  criteria

         12. Positive serology for HIV

         13. Positive serology for HTLV 1 or 2

         14. History of chronic or recurrent (within the last year) severe autoimmune or immune
             mediated disease requiring steroids or other immunosuppressive treatments. Subjects
             with history of idiopathic autoimmune hepatitis are excluded. Subjects who experienced
             hepatitis during treatment with check point inhibiting antibodies are not excluded.

         15. Subject has brain metastases.

         16. Other active malignancy besides HCC or other eligible AFP expressing tumor types
             within 3 years.

         17. Electrocardiogram (ECG) showing clinically significant abnormality at Screening or
             showing a QTc interval ≥450 msec in males and ≥470 msec in females (≥480 msec for
             subjects with Bundle Branch Block (BBB) over consecutive ECGs).

         18. Bacterial or opportunistic infection within 3 months of treatment (upper respiratory
             infection and uncomplicated urinary tract infection allowed)

         19. Uncontrolled intercurrent illness considered by the Investigator to add appreciable
             risk to study participation, including but not limited to:

               1. Clinically significant cardiac disease defined by CHF New York Heart Association
                  (NYHA) > Class 1; uncontrolled clinically significant arrhythmia in last 6
                  months; Acute Coronary Syndrome (ACS) (angina or myocardial infarction) in last 6
                  months.

               2. Oxygen dependent lung disease.

               3. Clinically significant psychiatric illness/social situations that would limit
                  compliance with study requirements.

               4. History of stroke or central nervous system bleeding; transient ischemic attack
                  (TIA) or reversible ischemic neurologic deficit (RIND) in last 6 months.

         20. Pregnant or breastfeeding

         21. Alcohol or illicit drug dependency

         22. Known contraindication to cyclophosphamide, fludarabine, mesna, G-CSF or other agents
             associated with study treatment.